# IMbrave 050 (NCT04102098)

> A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04102098
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Carcinoma, Hepatocellular
- Interventions: Atezolizumab; Bevacizumab
- Enrollment: 668
- Primary outcome: Recurrence-Free Survival (RFS), as Determined by IRF

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 84
- Podcasts: 40
- YouTube: 31
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=imbrave-050-nct04102098

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04102098", "email": "<work email>"}; the inbox owner confirms by the emailed link.